2019
Sa1745 – Glacial Acetic Acid-Induced Ulcerative Colitis Lesions Improve After Oral Calcium Nanoparticle Therapy in a Rat Model
Barahona M, Baratta V, Mulligan D, Geibel J. Sa1745 – Glacial Acetic Acid-Induced Ulcerative Colitis Lesions Improve After Oral Calcium Nanoparticle Therapy in a Rat Model. Gastroenterology 2019, 156: s-384. DOI: 10.1016/s0016-5085(19)37812-6.Peer-Reviewed Original ResearchDesign and implementation of novel nutraceuticals and derivatives for treating intestinal disorders
Barahona MJ, Baratta V, Ollodart J, Mulligan D, Geibel JP. Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders. Future Medicinal Chemistry 2019, 11: 847-855. PMID: 30994367, PMCID: PMC8008207, DOI: 10.4155/fmc-2018-0313.Peer-Reviewed Original ResearchConceptsSignificant worldwide disease burdenSpectrum of illnessWorldwide disease burdenIntestinal fluid secretionSystemic side effectsCalcium-sensing receptorNovel therapeutic targetG protein-coupled receptorsSurgical therapyPharmaceutical optionsMucosal integrityDisease burdenIntestinal disordersNutraceutical therapyGastrointestinal diseasesGastrointestinal illnessSide effectsTherapeutic targetFluid secretionIntestinal cellsTherapyAdverse effectsNovel nutraceuticalsCaSRIllness
2011
Endoscopic Treatment of Anastomotic Biliary Strictures After Living Donor Liver Transplantation: Outcomes After Maximal Stent Therapy
Hsieh T, Harrison M, Crowell M, Mekeel K, Aqel B, Carey E, Byrne T, Vargas H, Douglas D, Rakela J, Reddy K, Moss A, Mulligan D. Endoscopic Treatment of Anastomotic Biliary Strictures After Living Donor Liver Transplantation: Outcomes After Maximal Stent Therapy. Clinical Gastroenterology And Hepatology 2011, 9: 184. DOI: 10.1016/j.cgh.2010.11.016.Peer-Reviewed Original Research
2009
Plasmapheresis therapy for rare but potentially fatal reaction to rituximab
Hastings D, Patel B, Torloni AS, Mookadam F, Betcher J, Moss A, Heilman R, Mazur M, Hamawi K, Mulligan D, Reddy K, Mekeel K, Chakkera H. Plasmapheresis therapy for rare but potentially fatal reaction to rituximab. Journal Of Clinical Apheresis 2009, 24: 28-31. PMID: 19156754, DOI: 10.1002/jca.20187.Peer-Reviewed Original ResearchConceptsPlasmapheresis therapyFatal reactionsClinical conditionsHigh-dose vasopressorsHospital day 5Human IgG1 monoclonal antibodyNear-fatal reactionsPatient's clinical conditionIgG1 monoclonal antibodyRituximab therapyInfusion reactionsSupportive careRespiratory compromiseMedical managementCD20 antigenSpecific treatmentDisease processDay 5RituximabMonoclonal antibodiesTherapyMedical communitySubsequent treatmentPlasmapheresisNumerous diseases
2008
RISK FACTORS FOR ANTIBODY MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX) RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND RATG THERAPY
Moss A, Heilman R, Chakkera H, Mazur M, Petrides S, Wosniak E, Mekeel K, Mulligan D, Reddy K. RISK FACTORS FOR ANTIBODY MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX) RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND RATG THERAPY. Transplantation 2008, 86: 591-592. DOI: 10.1097/01.tp.0000330970.94094.7a.Peer-Reviewed Original Research
2006
THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY.
Moss A, Heilman R, Mazur M, Chakkera H, Wozniak E, Post D, Mulligan D, Reddy K. THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY. Transplantation 2006, 82: 292. DOI: 10.1097/00007890-200607152-00679.Peer-Reviewed Original ResearchAnti-thymocyte globulin induction therapyLow-dose intravenous immunoglobulinDose intravenous immunoglobulinFlow cytometry crossmatchDonor-specific antibodiesKidney transplant recipientsCytometry crossmatchInduction therapyIntravenous immunoglobulinTransplant recipientsCrossmatchTherapyImmunoglobulinRecipientsAntibodiesRESOURCE UTILIZATION IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B CELL, FLOW B AND/OR T CELL CROSS MATCH TREATED WITH LOW DOSE IVIG AND THYMOGLOBULIN® INDUCTION THERAPY.
Post D, Moss A, Mulligan D, Heilman R, Mazur M, Chakkera H, Reddy K. RESOURCE UTILIZATION IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B CELL, FLOW B AND/OR T CELL CROSS MATCH TREATED WITH LOW DOSE IVIG AND THYMOGLOBULIN® INDUCTION THERAPY. Transplantation 2006, 82: 668. DOI: 10.1097/00007890-200607152-01815.Peer-Reviewed Original Research